Adaptive Biotechnologies (ADPT) to Release Earnings on Thursday

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) is set to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Adaptive Biotechnologies to post earnings of ($0.30) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.31) EPS for the quarter, beating analysts' consensus estimates of ($0.33) by $0.02. The company had revenue of $43.19 million during the quarter, compared to analysts' expectations of $38.63 million. Adaptive Biotechnologies had a negative return on equity of 60.99% and a negative net margin of 126.49%. Adaptive Biotechnologies's revenue for the quarter was down 11.7% on a year-over-year basis. During the same period last year, the business posted ($0.33) EPS. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Stock Performance

Shares of ADPT traded down $0.22 during mid-day trading on Thursday, hitting $4.84. 1,597,786 shares of the company's stock were exchanged, compared to its average volume of 1,414,725. The stock's 50-day moving average is $4.70 and its 200-day moving average is $4.01. Adaptive Biotechnologies has a fifty-two week low of $2.28 and a fifty-two week high of $5.80. The company has a market cap of $713.26 million, a price-to-earnings ratio of -3.25 and a beta of 1.44.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. increased their target price on shares of Adaptive Biotechnologies from $5.00 to $6.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. BTIG Research increased their price objective on Adaptive Biotechnologies from $7.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, October 2nd. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $6.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.